Background {#Sec1}
==========

Despite the significant improvement in outcomes after the Fontan operation, complications and comorbidities are still common \[[@CR1], [@CR2]\]. Optimizing the Fontan circuit is an important factor in reducing these comorbidities \[[@CR3]\]. Cardiovascular magnetic resonance (CMR) has been shown to be a valuable tool to predict adverse outcomes in Fontan patients. One of the quantitative measurements by CMR is blood flow to each branch pulmonary artery \[[@CR4], [@CR5]\]. Studies evaluating Fontan patients have suggested that up to 45% of patients have maldistribution of pulmonary blood flow (MPBF), defined as a difference between left pulmonary artery (LPA) and right pulmonary artery (RPA) blood flow of \> 20% \[[@CR4]\].

The etiology of MPBF in the Fontan circulation is likely multifactorial due to different anatomic and physiologic abnormalities \[[@CR6]\]. Some studies suggest that the LPA can become compressed by the aortic root or ascending aorta, especially in patients with hypoplastic left heart syndrome (HLHS) \[[@CR7]\]. RPA twisting may be associated with the extracardiac Fontan modification \[[@CR8]\]. Lung pathologies including pulmonary hypoplasia and pulmonary vascular disease are common in Fontan physiology and may also result in MPBF \[[@CR6]\]. Furthermore, compression of pulmonary venous return may occur due to atrial dilation or by the Fontan conduit or baffle \[[@CR9], [@CR10]\]. These subtle abnormalities can lead to MPBF which may result in adverse hemodynamics. The associations of MPBF with exercise capacity and other clinical outcomes are largely unknown \[[@CR11], [@CR12]\]. The purpose of this study is to identify the impact of MPBF on exercise capacity and clinical outcomes in patients after the Fontan operation.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

A database search identified all post-operative Fontan patients who had a CMR study and cardiopulmonary exercise test (CPET) at Boston Children's Hospital between January 1999 and July 2017. Patients were included if differential branch pulmonary artery (PA) flow could be calculated by CMR and if they had a maximal effort on exercise stress testing, defined as a respiratory exchange ratio of ≥1.09 or a heart rate of ≥75% predicted. Patients were excluded if there were any interventions or procedures between the CMR and CPET or if the period between CPET and CMR was more than 2 years. The Boston Children's Hospital Committee on Clinical Investigation approved this retrospective study and waived the requirement for informed consent.

CMR {#Sec4}
---

CMR studies were performed with 1.5 Tesla scanners (Philips Healthcare, Best, the Netherlands or GE Medical Systems, Milwaukee, Wisconsin). The details of the CMR protocols used in our laboratory for assessment of patients after the Fontan operation have been published \[[@CR13]--[@CR15]\]. Briefly, ventricular assessment was performed by an electrocardiographically-gated, balanced steady-state free precession (bSSFP) cine CMR in vertical and horizontal ventricular long-axis planes, and a stack of slices in a ventricular short-axis plane encompassing the atrioventricular junction through the cardiac apex. Retrospectively cardiac gated, free-breathing, through-plane phase-contrast flow meaurements were obtained in the branch pulmonary arteries and vena cavae. Care was taken to align the imaging plane perpendicular to flow and to obtain slice positions and orientations that were proximal to the PA branching \[[@CR4]\].

CMR data analysis {#Sec5}
-----------------

If a patient had multiple CMR studies, the most recent study with complete flow data was used for analysis. MPBF was calculated by direct measurement of the branch PA flow on phase contrast imaging. Branch PA flow was measured by manually tracing each branch PA on phase contrast imaging using QFlow (Medis Medical Imaging Systems, Leiden, The Netherlands) (Fig. [1a](#Fig1){ref-type="fig"}) \[[@CR16]\]. Percentage flow to each PA was calculated. In patients without baffle leaks or patent fenestrations who had unilateral PA stents where direct PA flow could not be measured, flow in the stented PA was calculated using the following formula: superior vena cava flow+ inferior vena cava flow -- the non-stented branch PA flow. Branch PA cross-sectional area was calculated by measuring two orthogonal dimensions at the narrowest segment and indexed to body surface area (Fig. [1b](#Fig1){ref-type="fig"}). A branch PA symmetry index (PASI) was calculated as the ratio of the area of the smaller pulmonary artery to the larger pulmonary artery. PASI is always ≤1 with values closer to 1 reflecting more symmetric branch PAs \[[@CR17]\]. PA compression by the ascending aorta or aortic root was determined by review of CMR images by a provider who was blinded to the PA blood flow distribution. PA compression was defined as narrowing of the branch PA to \< 75% of its original diameter as it crossed posterior to the ascending aorta or the aortic root (Fig. [1c](#Fig1){ref-type="fig"}) \[[@CR18]\]. Lung volumes were calculated by Simpson's method using manual tracing of the lung fields in each slice on an axial image bSSFP stack (Fig. [1d](#Fig1){ref-type="fig"}). Lung volume discrepancy was defined as the absolute value of the difference between the right and left lung volume percentage. Aortic root total area was measured by adding dominant to non-dominant aortic root area as measured on axial planes \[[@CR19]\].Fig. 1Cardiovascular magnetic resonance (CMR) example of different measurements used in our study. **a** Branch pulmonary artery (PA) flow measurement. **b** Branch PA cross-sectional area was calculated by measuring two orthogonal dimensions at the narrowest segment. **c** Left pulmonary artery (LPA) compression by a dilated ascending aorta. **d** Lung volume calculation by Simpson's method using manual tracing in each slice on an axial image balanced steady-state free precession stack

Ventricular volumes and function were measured by manual tracing of endocardial and epicardial borders on each short-axis bSSFP cine slice at end-diastole (maximal volume) and end-systole (minimal volume) as previously described \[[@CR5], [@CR15]\]. Analysis was performed using commercially available software (QMass, Medis Medical Imaging Systems, Leiden, The Netherlands) and (cmr^42^, Circle Cardiovascular Imaging Inc., Calgary, Canada).

Clinical parameters {#Sec6}
-------------------

Demographic and clinical data, including underlying diagnoses and type of single ventricle based on ventricular dominance, were abstracted from the medical records. The type of surgical palliation was classified as lateral tunnel, extracardiac conduit, right atrium-to-PA anastomosis, or right atrium-to-right ventricle connection. Additional parameters included age at Fontan, time from Fontan to CMR, and number and type of surgical and catheterization interventions before and after CMR. Arrhythmia history was compiled by review of Holter monitors, electrocardiograms, electrophysiology catheterizations, and clinic notes. Other relevant clinical variables included a history of heart failure (defined as New York Heart Association class II or greater), protein-losing enteropathy, stroke, thrombus, seizures, liver disease, or pacemaker or defibrillator placement.

Cardiopulmonary exercise testing {#Sec7}
--------------------------------

A maximal CPET was performed using a calibrated cycle ergometer and ramp protocol (Corival Load Cycle 400, Lode BV, Groningen, The Netherlands). The test starts with setting an initial work rate based on the patient's body surface area (BSA) with linear increases every minute reaching a peak exercise after 10 min. Gas exchange was analyzed at rest, during exercise, and during recovery to determine measures of oxygen uptake (VO~2~) \[[@CR20]\]. Since peak VO~2~ is influenced by age, sex, and body weight, the percent of predicted peak VO~2~ value (% predicted VO~2~) was used due to the wide age range in this study \[[@CR21]\].

Statistical analysis {#Sec8}
--------------------

The Student t-test or Mann-Whitney U test was used to compare two groups of continuous symmetric or non-symmetric variables, respectively, or Fisher exact for categorical variables, as appropriate. A normal approximation to binomial confidence interval was constructed for the percentage of patients with MPBF. Univariate association between normally distributed variables was estimated using the Pearson correlation coefficient. A stepwise multivariable linear regression modeling procedure with 0.1 as the significance level for entry and 0.05 as the significance level for retention in the model was constructed to determine independent predictors of % predicted VO~2~. A stepwise multivariable logistic regression model with 0.1 as the significance level for entry and 0.05 as the significance level for retention in the model was constructed to identify the independent factors associated with the presence or absence of MPBF. Continuous predictor variables were also categorized into tertiles to assess potential nonlinearity, but no nonlinear significant associations were found (data not shown). All *p*-values were two-tailed (where applicable) and differences and associations were considered significant when *p* \< 0.05. Statistical analyses were performed using SPSS Statistics for Windows, Version 24.0 (International Business Machines, Armonk, New York, USA) and JMP®, Version 12 (SAS Institute Inc., Cary, North Carolina, USA).

Results {#Sec9}
=======

There were 147 patients who met inclusion criteria with complete CMR PA blood flow data and CPET without interval intervention. Most patients had direct PA blood flow assessment in both PAs; there were 3 patients who had a PA stent requiring calculation using venae cavae flow measurements. The median age at CMR was 21.8 years \[interquartile range (IQR) 16.5--30.6\]. The median time between CMR and CPET was 2.8 months \[IQR 0--13.8\]. There was no significant difference in the time from CMR to CPET between patients with and without MPBF. Patient characteristics are summarized in Table [1](#Tab1){ref-type="table"} \[[@CR4]\].Table 1Patient Demographic and Clinical CharacteristicsAll Patients (*n* = 147)Patients with MPBF (*n* = 53)Patients without MPBF (*n* = 94)*P* ValueAge at Fontan (yr)+3.2 \[2.2--6\]2.9 \[2--4.8\]3.3 \[2.3--7.6\]0.21Age at CMR (yr)21.8 \[16.5--30.6\]20.7 \[16.5--25\]23.2 \[16.6--32.2\]0.20Time since Fontan (yr)17.2 \[13.1--22.9\]16.5 \[13.1--20.9\]17.9 \[12.9--23.9\]0.23Time between CMR and CPET (mos)2.8 \[0--13.8\]1 \[0--14.5\]4.5 \[0--11.5\]0.10Body surface area at CMR (m^2^)1.7 \[1.5--1.9\]1.7 \[1.5--1.8\]1.7 \[1.5--2\]0.52Cardiac Diagnosis0.14 Tricuspid atresia37 (25%)14 (26%)23 (24%) Double-inlet left ventricle24 (16%)7 (13%)17 (18%) HLHS25 (17%)14 (26%)11 (12%) Unbalanced AV canal9 (6%)4 (8%)5 (5%) Double-outlet right ventricle25 (17)9 (17%)16 (17%) Complex 2 ventricle13 (9%)2 (4%)11 (12%) Hypoplastic TV/RV6 (4%)0 (0%)6 (7%) Pulmonary atresia/IVS2 (1%)1 (2%)1 (1%) Mitral atresia6 (4%)2 (4%)4 (4%)Levocardia122 (83%)78 (83%)44 (83%)0.90HLHS only25 (17%)14 (26%)11 (12%)0.04Heterotaxy17 (12%)8 (16%)9 (10%)0.23Genetic diagnosis11 (7%)5 (9%)6 (6%)0.45Dominant ventricular morphology0.68 Left ventricle58 (40%)19 (42%)39 (42%) Right ventricle49 (33%)20 (32%)29 (31%) 2 ventricles40 (27%)14 (26%)26 (27%)History of neonatal surgery79 (54%)34 (64%)45 (48%)0.06History of Glenn operation75 (51%)33 (62%)39 (41%)0.02History of Damus-Kaye-Stansel42 (29%)21 (40%)21 (22%)0.04Bilateral Glenn operation13 (8.8%)5 (10%)8 (10%)0.50Fontan Type0.43 Lateral tunnel98 (67%)41 (77%)57 (60%) RA-Pulmonary artery31 (21%)8 (15%)23 (25%) Extracardiac11 (8%)3 (6%)8 (11%) RA-RV Fontan5 (3.4%)1 (2%)4 (4%)History of any PA intervention^a^34 (23%)20 (38%)13 (14%)0.004 History of PA intervention before Fontan12 (8%)10 (19%)2 (2%)0.001 History of PA intervention at Fontan3 (2%)1 (2%)2 (2%)0.70 History of PA intervention after Fontan19 (13%)10 (19%)9 (10%)0.09Pulmonary vein stenosis^a^5 (3%)4 (7%)1 (1%)0.06*Abbreviations*: *AV* atrioventricular, *CMR* cardiovascular magnetic resonance, *CPET* cardiopulmonary exercise test, *HLHS* hypoplastic left heart syndrome, *IVS* intact ventricular septum, *MPBF* maldistribution of pulmonary blood flow, *PA* pulmonary artery, *RA* right atrium, *RV* right ventricle, *TV* tricuspid valve^a^Prior to CMR. + Data presented as median \[interquartile range\]

Distribution of pulmonary blood flow {#Sec10}
------------------------------------

MPBF was present in 53 patients (36%, 95% CI 29--45%). A histogram of differential PA blood flow is shown in Fig. [2](#Fig2){ref-type="fig"}. Total PA blood flow was 2.46 ± 0.6 L/m^2^. Average LPA blood flow was 1.07 ± 0.35 L/m^2^ which represented 44 ± 12% of total PA flow. Average RPA blood flow was 1.38 ± 0.44 L/m^2^ which represented 56 ± 11% of total PA flow. There was a weak correlation between branch PA flow percentage and ipsilateral PA cross-sectional area and less than 10% of the variability can be explained by cross sectional area (r^2^ \< 0.1) (Fig. [3](#Fig3){ref-type="fig"}). Similarly there was a weak correlation between branch PA flow percentage and lung volume percentage (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2Percentage difference in branch PA blood flow between the two branch PAs. The mean branch PA flow is 56% to the right PA. Green denotes no MPBF (%difference \< 20); yellow denotes MPBF (%difference ≥ 20). MPBF: Maldistribution of pulmonary blood flow. PA: Pulmonary artery. PBF: Pulmonary blood flowFig. 3Association between branch PA flow percentage and lung volume percentage (**a**, **b**) and ipsilateral PA cross sectional area (**c**, **d**). *N* = 140. The estimate r denotes Pearson correlation coefficient. LPA: Left pulmonary artery. RPA: Right pulmonary artery. Log: Logarithmic transformation

MPBF and exercise capacity {#Sec11}
--------------------------

The mean % predicted VO~2~ was 63 ± 16%. Patients with MPBF had lower % predicted VO~2~ compared to patients without MPBF (60 ± 14% versus 65 ± 16%; *p* = 0.04) (Fig. [4](#Fig4){ref-type="fig"}). Additional univariate associations of lower % predicted VO~2~ are shown in Table [2](#Tab2){ref-type="table"} and included longer time since Fontan, older age at the Fontan operation, atriopulmonary connection Fontan, heart failure symptoms, presence of a fenestration, and a higher ventricular mass-to-volume ratio. On multivariable analysis, only MPBF, time since Fontan, and ventricular mass-to-volume ratio were associated with a lower % predicted VO~2~ (Table [3](#Tab3){ref-type="table"}).Fig. 4Patients with maldistribution of pulmonary blood flow (MPBF, *n* = 53; yellow) had lower mean % predicted peak VO~2~ compared to patients with no MPBF (*n* = 94, green). Error bars denote one standard deviationTable 2Univariate Associations with % Predicted VO~2~PredictorR or standardized βParameter Estimate ± SE*P* valueMaldistribution of pulmonary blood flow (*n* = 147)−0.17−5.4 ± 2.6^a^0.04Mass-to-volume ratio (g/ml) (*n* = 140)− 0.24−19.38 ± 6.60^b^0.004Age at Fontan (year) (*n* = 139)− 0.20− 0.47 ± 0.19^b^0.02Old type Fontan (RA-PA or RA-RV conduit) (*n* = 146)− 0.27−9.2 ± 2.8^a^0.001CHF symptoms (*n* = 146)− 0.21−7.6 ± 2.9^a^0.01Atrial arrhythmia (*n* = 146)− 0.29−9.4 ± 2.6^a^0.001Fenestration (*n* = 139)− 0.17−1 ± 0.4^a^0.04Age at CMR (year) (*n* = 146)− 0.36− 0.55 ± 0.12^b^0.001Time since Fontan (year) (*n* = 139)− 0.30−0.67 ± 0.18^b^0.001Indexed end diastolic volume (ml/m^2^) (*n* = 145)0.10−0.03 ± 0.04^b^0.90Indexed end systolic volume (ml/m^2^) (*n* = 145)−0.10−0.07 ± 0.05^b^0.16Ejection fraction (%) (*n* = 145)0.100.23 ± 0.14^b^0.15Indexed stroke volume (ml/m^2^) (*n* = 145)0.010.01 ± 0.10^b^0.94Branch pulmonary artery symmetry index (*n* = 147)0.042.52 ± 5.52^b^0.64Systemic left ventricle (*n* = 144)0.01−0.5 ± 3.0^a^0.84Heterotaxy (*n* = 147)0.01−3.3 ± 4.0^a^0.41*Abbreviations*: *PA* pulmonary artery, *RA* right atrium, *RV* right ventricle^a^Mean difference ± SE for presence vs. absence of maldistribution of pulmonary blood flow^b^Slope ± SE.SE = standard errorTable 3Multivariable Model for % Predicted VO~2~ (*n* = 140)VariableStandardized β coefficientParameter Estimate ± SE*P* valueMaldistribution of pulmonary blood flow−0.20−5.4 ± 2.6^a^0.03Time since Fontan (year)−0.32−0.67 ± 0.18^b^0.002Ventricular mass-to-volume ratio (g/ml)−0.24−19.38 ± 6.60^b^0.02^a^Mean difference ± SE for presence vs. absence of maldistribution of pulmonary blood flow^b^Slope ± SE.SE = standard error

MPBF and clinical outcomes {#Sec12}
--------------------------

During a median follow-up period of 4.2 years \[IQR 2.1--8.4\] after the CMR, 14 (10%) patients died or were listed for heart transplant. Of the 10 patients who died, deaths were attributed to arrhythmias (*n* = 4), heart failure (*n* = 4), renal failure (*n* = 1), and protein losing enteropaty (*n* = 1). The follow-up period was similar among those with and without MPBF (Table [4](#Tab4){ref-type="table"}). MPBF was not associated with death or listing for transplant (*p* = 0.60). MPBF was not associated with other comorbidities including atrial flutter, heart failure, protein-losing enteropathy, major thrombotic events, liver disease, or stroke (Table [4](#Tab4){ref-type="table"}).Table 4Clinical Outcomes in Patients with and without MPBFAll patientsWith MPBFWithout MPBFP value^\*^(*n* = 147)(*n* = 53)(*n* = 94) Follow-up time post CMR (year)4.2 \[2.1--8.4\]4.1 \[1.7--9.1\]4.4 \[2.4--8.9\]0.59 Death10 (7%)4 (8%)6 (6%)0.70 Death / listing for transplantation14 (10%)6 (11%)8 (9%)0.60 Liver disease50 (34%)16 (30%)34 (36%)0.58 Heart failure35 (24%)15 (29%)20 (22%)0.42 Thrombus28 (19%)12 (22%)16 (17%)0.50 Seizures16 (11%)6 (11%)10 (11%)0.90 Stroke26 (18%)11 (21%)15 (17)0.50 Protein-losing enteropathy5 (3%)1 (2%)4 (4%)0.40 Atrial flutter post-Fontan32 (22%)11 (21%)21 (22%)0.90*Abbreviations*: *MPBF* maldistribution of pulmonary blood flow^\*^Fisher exact test *p*-value for all variables except follow-up time (Mann-Whitney U Test)

Parameters associated with MPBF {#Sec13}
-------------------------------

On univariate analysis, a surgical history of a Damus-Kaye-Stansel anastomosis, having a cardiac diagnosis of HLHS, prior Glenn procedure, and history of prior PA intervention were associated with MPBF (Table [1](#Tab1){ref-type="table"}). The CMR parameters and their associations with MPBF are shown in Table [5](#Tab5){ref-type="table"}. On univariate analysis, MPBF was associated with larger ventricular volumes, increased aortopulmonary collateral flow, larger ascending aorta and aortic root cross-sectional areas, PA compression by the ascending aorta or aortic root, PASI, and larger lung volume discrepancies. On multivariable logistic regression analysis, only PA compression by the ascending aorta or aortic root was associated with MPBF (OR = 6.5, 95% confidence interval 5.6--7.4, *p* \< 0.001). Branch PA compression was seen in 32 patients (21%), and involved the LPA in 30 patients and the RPA in 2 patients.Table 5CMR Parameter Associations with MPBFAll patients (*n* = 147)With MPBF (*n* = 53)Without MPBF (*n* = 94)*P* valueVentricular end-diastolic volume (ml/BSA^1.3^)98 ± 29104 ± 3594 ± 250.05Ventricular end-systolic volume (ml/BSA^1.3^)49 ± 2554 ± 2646 ± 190.04Aortopulmonary collateral flow (%)12 \[3--23\]16 \[4--27\]10 \[3--20\]0.02Ascending aorta area (cm^2^)4.9 ± 2.75.8 ± 3.74.4 ± 1.90.001Total aortic root area (cm^2^)6.9 ± 1.95.6 ± 1.75.1 ± 1.80.03Pulmonary artery symmetry index (%)65 ± 2459 ± 2568 ± 230.02Pulmonary artery compression by the ascending aorta or aortic root32 (22%)21 (39%)11 (12%)0.001Lung volume percentage difference (%)13 ± 915 ± 712 ± 90.04Indexed ventricular stroke volume (ml/m^2^)57 ± 1160 ± 1356 ± 120.55Ventricular mass-to-volume ratio (gram/ml)0.55 ± 0.190.53 ± 0.200.58 ± 0.180.13Indexed Ventricular mass (g/m^2^)61.8 ± 1962.0 ± 2161.7 ± 180.77Abbreviations: MPBF: maldistribution of pulmonary blood flow; BSA: body surface area

Discussion {#Sec14}
==========

This study evaluated the PA blood flow distribution in 147 patients with a Fontan circulation. Patients with MPBF, defined as a difference between LPA and RPA blood flow of \> 20%, had lower exercise capacity compared to patients without MPBF. Previous studies have shown that % predicted VO~2~ is an independent predictor of mortality in Fontan patients with a hazard ratio of 0.88 for each 1% increase in % predicted VO~2~ \[[@CR22]\]. This would imply that our measured difference of 5% predicted VO~2~ is likely clinically significant. There were no other associations between MPBF and other clinical outcomes, including death or listing for transplantation. Patients with PA compression by a dilated ascending aorta or aortic root were the most likely to have MPBF.

Previous investigators have used CMR to evaluate PA blood flow distribution in normal subjects and patients with a Fontan circulation \[[@CR4]\]. In individuals without congenital heart disease, 55% of PA blood flow is through the RPA and 45% through the LPA. This difference has been attributed to the smaller left lung volume due to the heart being in the left side of the chest \[[@CR23]\]. In Fontan patients, Whitehead et al. demonstrated that, on average, RPA flow is 55% of the total PA flow. Likewise, our study showed similar flow to the RPA (56% of total PA blood flow) \[[@CR24]\]. Both our study and previous studies revealed wide variations in PA blood flow distribution in Fontan patients. Whitehead et al. showed that the prevalence of MPBF is about 45%; however, the study was not designed to look at the associations with clinical outcomes or exercise capacity \[[@CR4]\]. In our cohort, MPBF was common, seen in 36% of patients. The variability of PA blood flow distribution in our study is likely multifactorial and can be only partially explained by lung volume discrepancy as there was only a weak association with lung volumes.

Many variables were associated with MPBF in univariate analysis. On multivariable analysis, only branch PA compression by the ascending aorta or the aortic root had a significant association with MPBF. Previous studies showed that severe aortic root dilation or ascending aortic dilation is seen commonly in patients with Fontan circulation and was associated with aortic regurgitation \[[@CR25]\]. Our study suggests that another adverse effect of aortic dilation is PA compression which can lead to MPBF, especially in patients with a left aortic arch leading to LPA compression. PA compression by the aortic root and the ascending aorta was recognized as a problem after the Stage I palliation that can lead to long-term PA hypoplasia in previous studies \[[@CR26]--[@CR28]\]. This resulted in multiple modifications of the surgical technique including changing the direction of the Blalock-Taussig shunt leftward into the retroaortic PA to avoid development of LPA stenosis and using more ring-enforced RV-PA conduits in addition to patch augmentation of the LPA \[[@CR26]--[@CR28]\].

Our study as with others found significant exercise impairment in Fontan patients (mean % predicted VO~2~ of 63%) \[[@CR22], [@CR29]\]. Previously reported determinants of exercise capacity include the inability to increase stroke volume at peak exercise, chronotropic impairment, diastolic dysfunction, and power loss in the Fontan circulation \[[@CR30], [@CR31]\]. Non-cardiac factors including age, muscle mass and conditioning are also important determinants \[[@CR30], [@CR31]\]. In addition to confirming the independent association of time since Fontan and ventricular mass-to-volume ratio with exercise capacity, our study introduces MPBF as another factor that adversely affects exercise capacity in the Fontan population.

We found a weak correlation between ipsilateral PA blood flow and PA size. These data would suggest that reliance solely on PA size (either by echocardiography or angiography) might not correlate well with differential PA blood flow. Direct PA blood flow assessment by CMR should be preferred.

MPBF may result in ventilation perfusion mismatch and less efficient gas exchange within the lungs \[[@CR32]\]. MPBF, especially in the case of branch PA stenosis or compression, may also result in elevated Fontan baffle pressures which could lead to an increase in veno-venous collaterals to the pulmonary veins, which can cause systemic desaturation \[[@CR33]\]. Fontan patients with severe unilateral branch PA stenosis have been noted to have significantly lower saturations compared to patients without stenosis \[[@CR33]\]. Lower oxygen saturation has also been associated with lower exercise capacity in patients with congenital heart disease \[[@CR4], [@CR34], [@CR35]\]. Finally, MPBF may also be associated with significant power loss in the Fontan circuit. Previous elegant work using computational flow dynamics showed that power loss correlates to the minimum cross sectional PA area in Fontan patients \[[@CR36]\]. MPBF may be a surrogate for the potential power loss in the Fontan circuit \[[@CR37]\]. It is also plausible that during exercise, the differences in PA blood flow may be magnified. This may explain why a small measured effect in MPBF at rest has significant impact on functional exercise capacity. Future real time CMR studies during exercise may increase our understanding of the relationships between MPBF, power loss, and exercise capacity.

Limitations {#Sec15}
-----------

This is a single-center CMR study which may limit the generalizability of these results to all Fontan patients. In particular, patients with pacemakers and defibrillators could not be evaluated; these devices are used in 13% of patients with Fontan circulation \[[@CR37]\]. Sicker patients and patients with symptoms could be over-represented in this study, as these patients are more likely to be evaluated by CMR \[[@CR38]\]. Also, 78 patients were excluded due to the incomplete flow data. Many of these patients had branch PA stents and may have had severe MPBF. Finally, this study included only patients with a maximal CPET, which limited the sample size and may have caused selection bias toward patients with higher functional status.

Conclusion {#Sec16}
==========

In patients after the Fontan operation, MPBF was common, seen in more than one third of patients. Lower exercise capacity was independently associated with MPBF, longer time since Fontan, and increased ventricular mass-to-volume ratio. Patients with PA compression by the aortic root or the ascending aorta were more likely to have MPBF. This study identifies MPBF as an important risk factor and as a potential target for therapeutic interventions in this fragile patient population.
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